Research ArticleNEUROPHARMACOLOGY
The Anxioselective Agent 7-(2-Chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) Is More Efficacious Than Diazepam at Enhancing GABA-Gated Currents at α1 Subunit-Containing GABAA Receptors
Piotr Popik, Emmanuel Kostakis, Martyna Krawczyk, Gabriel Nowak, Bernadeta Szewczyk, Philip Krieter, Zhengming Chen, Shelley J. Russek, Terrell T. Gibbs, David H. Farb, Phil Skolnick, Arnold S. Lippa and Anthony S. Basile
Journal of Pharmacology and Experimental Therapeutics December 2006, 319 (3) 1244-1252; DOI: https://doi.org/10.1124/jpet.106.107201
Piotr Popik
Behavioral Neuroscience (P.P., M.K.) and Department of Neurobiology (G.N., B.S.), Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland; Laboratory of Molecular Neurobiology, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts (E.K., S.J.R., T.T.G., D.H.F.); Department of Cytobiology and Histochemistry, Collegium Medicum, Jagiellonian University, Krakow, Poland (G.N.); and DOV Pharmaceutical, Inc., Somerset, New Jersey (P.K., Z.C., P.S., A.S.L., A.S.B.)
Emmanuel Kostakis
Behavioral Neuroscience (P.P., M.K.) and Department of Neurobiology (G.N., B.S.), Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland; Laboratory of Molecular Neurobiology, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts (E.K., S.J.R., T.T.G., D.H.F.); Department of Cytobiology and Histochemistry, Collegium Medicum, Jagiellonian University, Krakow, Poland (G.N.); and DOV Pharmaceutical, Inc., Somerset, New Jersey (P.K., Z.C., P.S., A.S.L., A.S.B.)
Martyna Krawczyk
Behavioral Neuroscience (P.P., M.K.) and Department of Neurobiology (G.N., B.S.), Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland; Laboratory of Molecular Neurobiology, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts (E.K., S.J.R., T.T.G., D.H.F.); Department of Cytobiology and Histochemistry, Collegium Medicum, Jagiellonian University, Krakow, Poland (G.N.); and DOV Pharmaceutical, Inc., Somerset, New Jersey (P.K., Z.C., P.S., A.S.L., A.S.B.)
Gabriel Nowak
Behavioral Neuroscience (P.P., M.K.) and Department of Neurobiology (G.N., B.S.), Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland; Laboratory of Molecular Neurobiology, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts (E.K., S.J.R., T.T.G., D.H.F.); Department of Cytobiology and Histochemistry, Collegium Medicum, Jagiellonian University, Krakow, Poland (G.N.); and DOV Pharmaceutical, Inc., Somerset, New Jersey (P.K., Z.C., P.S., A.S.L., A.S.B.)
Bernadeta Szewczyk
Behavioral Neuroscience (P.P., M.K.) and Department of Neurobiology (G.N., B.S.), Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland; Laboratory of Molecular Neurobiology, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts (E.K., S.J.R., T.T.G., D.H.F.); Department of Cytobiology and Histochemistry, Collegium Medicum, Jagiellonian University, Krakow, Poland (G.N.); and DOV Pharmaceutical, Inc., Somerset, New Jersey (P.K., Z.C., P.S., A.S.L., A.S.B.)
Philip Krieter
Behavioral Neuroscience (P.P., M.K.) and Department of Neurobiology (G.N., B.S.), Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland; Laboratory of Molecular Neurobiology, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts (E.K., S.J.R., T.T.G., D.H.F.); Department of Cytobiology and Histochemistry, Collegium Medicum, Jagiellonian University, Krakow, Poland (G.N.); and DOV Pharmaceutical, Inc., Somerset, New Jersey (P.K., Z.C., P.S., A.S.L., A.S.B.)
Zhengming Chen
Behavioral Neuroscience (P.P., M.K.) and Department of Neurobiology (G.N., B.S.), Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland; Laboratory of Molecular Neurobiology, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts (E.K., S.J.R., T.T.G., D.H.F.); Department of Cytobiology and Histochemistry, Collegium Medicum, Jagiellonian University, Krakow, Poland (G.N.); and DOV Pharmaceutical, Inc., Somerset, New Jersey (P.K., Z.C., P.S., A.S.L., A.S.B.)
Shelley J. Russek
Behavioral Neuroscience (P.P., M.K.) and Department of Neurobiology (G.N., B.S.), Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland; Laboratory of Molecular Neurobiology, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts (E.K., S.J.R., T.T.G., D.H.F.); Department of Cytobiology and Histochemistry, Collegium Medicum, Jagiellonian University, Krakow, Poland (G.N.); and DOV Pharmaceutical, Inc., Somerset, New Jersey (P.K., Z.C., P.S., A.S.L., A.S.B.)
Terrell T. Gibbs
Behavioral Neuroscience (P.P., M.K.) and Department of Neurobiology (G.N., B.S.), Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland; Laboratory of Molecular Neurobiology, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts (E.K., S.J.R., T.T.G., D.H.F.); Department of Cytobiology and Histochemistry, Collegium Medicum, Jagiellonian University, Krakow, Poland (G.N.); and DOV Pharmaceutical, Inc., Somerset, New Jersey (P.K., Z.C., P.S., A.S.L., A.S.B.)
David H. Farb
Behavioral Neuroscience (P.P., M.K.) and Department of Neurobiology (G.N., B.S.), Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland; Laboratory of Molecular Neurobiology, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts (E.K., S.J.R., T.T.G., D.H.F.); Department of Cytobiology and Histochemistry, Collegium Medicum, Jagiellonian University, Krakow, Poland (G.N.); and DOV Pharmaceutical, Inc., Somerset, New Jersey (P.K., Z.C., P.S., A.S.L., A.S.B.)
Phil Skolnick
Behavioral Neuroscience (P.P., M.K.) and Department of Neurobiology (G.N., B.S.), Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland; Laboratory of Molecular Neurobiology, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts (E.K., S.J.R., T.T.G., D.H.F.); Department of Cytobiology and Histochemistry, Collegium Medicum, Jagiellonian University, Krakow, Poland (G.N.); and DOV Pharmaceutical, Inc., Somerset, New Jersey (P.K., Z.C., P.S., A.S.L., A.S.B.)
Arnold S. Lippa
Behavioral Neuroscience (P.P., M.K.) and Department of Neurobiology (G.N., B.S.), Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland; Laboratory of Molecular Neurobiology, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts (E.K., S.J.R., T.T.G., D.H.F.); Department of Cytobiology and Histochemistry, Collegium Medicum, Jagiellonian University, Krakow, Poland (G.N.); and DOV Pharmaceutical, Inc., Somerset, New Jersey (P.K., Z.C., P.S., A.S.L., A.S.B.)
Anthony S. Basile
Behavioral Neuroscience (P.P., M.K.) and Department of Neurobiology (G.N., B.S.), Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland; Laboratory of Molecular Neurobiology, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts (E.K., S.J.R., T.T.G., D.H.F.); Department of Cytobiology and Histochemistry, Collegium Medicum, Jagiellonian University, Krakow, Poland (G.N.); and DOV Pharmaceutical, Inc., Somerset, New Jersey (P.K., Z.C., P.S., A.S.L., A.S.B.)
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleNEUROPHARMACOLOGY
The Anxioselective Agent 7-(2-Chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) Is More Efficacious Than Diazepam at Enhancing GABA-Gated Currents at α1 Subunit-Containing GABAA Receptors
Piotr Popik, Emmanuel Kostakis, Martyna Krawczyk, Gabriel Nowak, Bernadeta Szewczyk, Philip Krieter, Zhengming Chen, Shelley J. Russek, Terrell T. Gibbs, David H. Farb, Phil Skolnick, Arnold S. Lippa and Anthony S. Basile
Journal of Pharmacology and Experimental Therapeutics December 1, 2006, 319 (3) 1244-1252; DOI: https://doi.org/10.1124/jpet.106.107201
Research ArticleNEUROPHARMACOLOGY
The Anxioselective Agent 7-(2-Chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) Is More Efficacious Than Diazepam at Enhancing GABA-Gated Currents at α1 Subunit-Containing GABAA Receptors
Piotr Popik, Emmanuel Kostakis, Martyna Krawczyk, Gabriel Nowak, Bernadeta Szewczyk, Philip Krieter, Zhengming Chen, Shelley J. Russek, Terrell T. Gibbs, David H. Farb, Phil Skolnick, Arnold S. Lippa and Anthony S. Basile
Journal of Pharmacology and Experimental Therapeutics December 1, 2006, 319 (3) 1244-1252; DOI: https://doi.org/10.1124/jpet.106.107201
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement